Hot Investor Mandate: Growth Equity Fund Invests $20-60M in Revenue Generating Healthcare Companies in North America

7 Sep

A USA-based growth equity fund is investing out of its latest fund which closed last year. The firm makes equity investments in commercial stage (post regulatory approval) healthcare companies with meaningful revenue and traction. The firm typically invests between $20-60m per company, and focuses on companies in USA and Canada.

The firm invests exclusively in healthcare and is open to all sub-sectors within the industry including products and services. That said, the firm does not invest in pre-revenue companies or those with regulatory risk; investments are made in revenue-generating companies with products that have already received regulatory approval or which do not require regulatory approval. The firm looks for companies with meaningful marketplace validation and growing revenues, where the firm’s investment could help to accelerate the adoption.

The firm prefers to invest in management teams with experience in leading and growing businesses of scale and relevant industry experience.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a comment